Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Condition(s):Severe Aplastic Anemia; Platelet Transfusion RefractorinessLast Updated:February 12, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Severe Aplastic Anemia; Platelet Transfusion RefractorinessLast Updated:February 12, 2024Recruiting
Condition(s):Neuromyelitis Optica Spectrum DisorderLast Updated:October 19, 2020Completed
Condition(s):Multiple SclerosisLast Updated:October 14, 2021Recruiting
Condition(s):Epstein-Barr Virus Infections; Post-transplant Lymphoproliferative DisorderLast Updated:August 2, 2022Unknown status
Condition(s):Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating DiseasesLast Updated:April 28, 2023Recruiting
Condition(s):Rheumatoid ArthritisLast Updated:December 28, 2023Not yet recruiting
Condition(s):Multiple SclerosisLast Updated:September 7, 2018Completed
Condition(s):PemphigusLast Updated:March 13, 2024Active, not recruiting
Condition(s):DLBCL; MYD88 Gene Mutation; CD79A Gene Mutation; CD79B Gene Mutation; Relapse; Refractory LymphomaLast Updated:August 6, 2021Not yet recruiting
Condition(s):Diffuse Large B-cell Lymphoma; Rituximab; ToripalimabLast Updated:June 16, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.